{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:09:10Z","timestamp":1785798550459,"version":"3.56.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Activated protein C resistance (APCR) due to factor V Leiden (FVL) mutation (R506Q) is a major risk factor in patients with venous thromboembolism (VTE). The present study investigated the clinical manifestations and the risk of venous thromboembolism regarding multiple clinical, laboratory, and demographic properties in FVL patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>A retrospective cross-sectional analysis was conducted on a total of 288 FVL patients with VTE according to APCR. In addition, 288 VET control samples, without FVL mutation, were also randomly selected. Demographic information, clinical manifestations, family and treatment history were recorded, and specific tests including t-test, chi-square and uni- and multi-variable regression tests applied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>APCR was found to be 2.3 times significantly more likely in men (OR: 2.1, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) than women. The risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in APCR patients was 4.5 and 3.2 times more than the control group, respectively (<jats:italic>p\u2009&lt;<\/jats:italic>\u00a00.05). However, APCR could not be an independent risk factor for arterial thrombosis (AT) and pregnancy complications. Moreover, patients were evaluated for thrombophilia panel tests and showed significantly lower protein C and S than the control group and patients without DVT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>FVL mutation and APCR abnormality are noticeable risk factors for VTE. Screening strategies for FVL mutation in patients undergoing surgery, oral contraceptive medication, and pregnancy cannot be recommended, but a phenotypic test for activated protein C resistance should be endorsed in patients with VTE.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12959-021-00328-0","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T16:43:28Z","timestamp":1634661808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A case-control study on factor V Leiden: an independent, gender-dependent risk factor for venous thromboembolism"],"prefix":"10.1186","volume":"19","author":[{"given":"Vahideh","family":"Takhviji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Zibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz","family":"Hommayoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Tabatabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Esmaeil","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Soleymani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid Kiani","family":"Ghalesardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Farokhian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Davari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Paridar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahita","family":"Kalantari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5213-106X","authenticated-orcid":false,"given":"Abbas","family":"Khosravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"issue":"11","key":"328_CR1","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1093\/humrep\/deg474","volume":"18","author":"T Buchholz","year":"2003","unstructured":"Buchholz T, et al. Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod. 2003;18(11):2473\u20137.","journal-title":"Hum Reprod"},{"issue":"01","key":"328_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5482\/HAMO-16-09-0034","volume":"37","author":"JR Byrnes","year":"2017","unstructured":"Byrnes JR, Wolberg AS. New findings on venous thrombogenesis. H\u00e4mostaseologie. 2017;37(01):25\u201335.","journal-title":"H\u00e4mostaseologie"},{"issue":"43","key":"328_CR3","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","volume":"35","author":"ATF Members","year":"2014","unstructured":"Members ATF, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014;35(43):3033\u201380.","journal-title":"Eur Heart J"},{"issue":"1","key":"328_CR4","first-page":"452","volume":"2005","author":"M Cushman","year":"2005","unstructured":"Cushman M. Inherited risk factors for venous thrombosis. ASH Education Program Book. 2005;2005(1):452\u20137.","journal-title":"ASH Education Program Book"},{"issue":"3","key":"328_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1046\/j.1365-2141.2001.02981.x","volume":"114","author":"I Walker","year":"2001","unstructured":"Walker I, Greaves M, Preston F. On behalf of the Haemostasis and thrombosis task force British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol. 2001;114(3):512\u201328.","journal-title":"Br J Haematol"},{"issue":"2","key":"328_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.reprotox.2006.05.002","volume":"22","author":"M De Santis","year":"2006","unstructured":"De Santis M, et al. Inherited and acquired thrombophilia: pregnancy outcome and treatment. Reprod Toxicol. 2006;22(2):227\u201333.","journal-title":"Reprod Toxicol"},{"issue":"4","key":"328_CR7","first-page":"493","volume":"29","author":"D Singh","year":"2018","unstructured":"Singh D, et al. Genetics of hypercoagulable and Hypocoagulable states. Neurosurgery Clinics. 2018;29(4):493\u2013501.","journal-title":"Neurosurgery Clinics"},{"issue":"2","key":"328_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3122\/15572625-13-2-111","volume":"13","author":"DR Sheppard","year":"2000","unstructured":"Sheppard DR. Activated protein C resistance: the most common risk factor for venous thromboembolism. J Am Board Fam Pract. 2000;13(2):111\u20135.","journal-title":"J Am Board Fam Pract"},{"issue":"Suppl 1","key":"328_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ijlh.12508","volume":"38","author":"B Dahlback","year":"2016","unstructured":"Dahlback B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol. 2016;38(Suppl 1):4\u201311.","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"328_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.24222","volume":"91","author":"EM Van Cott","year":"2016","unstructured":"Van Cott EM, Khor B, Zehnder JL. Factor VL eiden. Am J Hematol. 2016;91(1):46\u20139.","journal-title":"Am J Hematol"},{"issue":"12","key":"328_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1080\/17474086.2016.1249364","volume":"9","author":"E Campello","year":"2016","unstructured":"Campello E, Spiezia L, Simioni P. Diagnosis and management of factor V Leiden. Expert Rev Hematol. 2016;9(12):1139\u201349.","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"328_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.transci.2017.11.021","volume":"56","author":"J Amiral","year":"2017","unstructured":"Amiral J, Vissac AM, Seghatchian J. Laboratory assessment of activated protein C resistance\/factor V-Leiden and performance characteristics of a new quantitative assay. Transfus Apher Sci. 2017;56(6):906\u201313.","journal-title":"Transfus Apher Sci"},{"issue":"15","key":"328_CR13","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2013-10-530089","volume":"123","author":"K Nogami","year":"2014","unstructured":"Nogami K, et al. Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden. Blood. 2014;123(15):2420\u20138.","journal-title":"Blood"},{"issue":"3","key":"328_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/j.1365-2141.1995.tb05610.x","volume":"90","author":"A Cumming","year":"1995","unstructured":"Cumming A, et al. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90(3):725\u20137.","journal-title":"Br J Haematol"},{"issue":"01","key":"328_CR15","first-page":"1360","volume":"78","author":"G Freyburger","year":"1997","unstructured":"Freyburger G, et al. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients. Thromb Haemost. 1997;78(01):1360\u20135.","journal-title":"Thromb Haemost"},{"key":"328_CR16","doi-asserted-by":"publisher","first-page":"107602962199681","DOI":"10.1177\/1076029621996813","volume":"27","author":"SE Ahmadi","year":"2021","unstructured":"Ahmadi SE, et al. Congenital combined bleeding disorders, a comprehensive study of a large number of Iranian patients. Clin Appl Thromb Hemost. 2021;27:1076029621996813.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"23","key":"328_CR17","doi-asserted-by":"publisher","first-page":"e018917","DOI":"10.1161\/JAHA.120.018917","volume":"9","author":"E Campello","year":"2020","unstructured":"Campello E, et al. Direct Oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study. J Am Heart Assoc. 2020;9(23):e018917.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"328_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1111\/jth.14532","volume":"17","author":"GW Moore","year":"2019","unstructured":"Moore GW, et al. Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH. J Thromb Haemost. 2019;17(9):1555\u201361.","journal-title":"J Thromb Haemost"},{"key":"328_CR19","doi-asserted-by":"crossref","unstructured":"Laffan M. Activated protein C resistance and myocardial infarction. BMJ Publishing Group Ltd. 1998.","DOI":"10.1136\/hrt.80.4.319"},{"issue":"3","key":"328_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s11239-007-0052-6","volume":"25","author":"Z Rahimi","year":"2008","unstructured":"Rahimi Z, et al. Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J Thromb Thrombolysis. 2008;25(3):280\u20133.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"328_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12687-011-0072-y","volume":"3","author":"H Hamamy","year":"2012","unstructured":"Hamamy H. Consanguineous marriages. J Community Genet. 2012;3(3):185\u201392.","journal-title":"J Community Genet"},{"issue":"3","key":"328_CR22","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1055\/s-0038-1657675","volume":"78","author":"PJ Svensson","year":"1997","unstructured":"Svensson PJ, et al. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty. Thromb Haemost. 1997;78(3):993\u20136.","journal-title":"Thromb Haemost"},{"issue":"6","key":"328_CR23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.thromres.2005.06.011","volume":"117","author":"EJ Favaloro","year":"2006","unstructured":"Favaloro EJ, et al. Activated protein C resistance: the influence of ABO-blood group, gender and age. Thromb Res. 2006;117(6):665\u201370.","journal-title":"Thromb Res"},{"issue":"01","key":"328_CR24","first-page":"0993","volume":"78","author":"P Svensson","year":"1997","unstructured":"Svensson P, et al. Female gender and resistance to activated protein C (FV: Q506) as potential risk factors for thrombosis after elective hip arthroplasty. Thromb Haemost. 1997;78(01):0993\u20136.","journal-title":"Thromb Haemost"},{"key":"328_CR25","doi-asserted-by":"crossref","unstructured":"Hansen RS, Nybo M. The association between activated protein C ratio and factor V Leiden are gender-dependent. Clin Chem Lab Med (CCLM). 2019.","DOI":"10.1515\/cclm-2018-1382"},{"issue":"3","key":"328_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00417-001-0415-1","volume":"240","author":"C Kuhli","year":"2002","unstructured":"Kuhli C, et al. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002;240(3):163\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"328_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.thromres.2019.07.030","volume":"182","author":"EH Federici","year":"2019","unstructured":"Federici EH, Al-Mondhiry H. High risk of thrombosis recurrence in patients with homozygous and compound heterozygous factor V R506Q (factor V Leiden) and prothrombin G20210A. Thromb Res. 2019;182:75\u20138.","journal-title":"Thromb Res"},{"issue":"8","key":"328_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","volume":"130","author":"F Rodeghiero","year":"1999","unstructured":"Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130(8):643\u201350.","journal-title":"Ann Intern Med"},{"issue":"14","key":"328_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1056\/NEJM199504063321403","volume":"332","author":"PM Ridker","year":"1995","unstructured":"Ridker PM, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332(14):912\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"328_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/00062752-199809000-00008","volume":"5","author":"M Thorogood","year":"1998","unstructured":"Thorogood M. Oral contraceptives and thrombosis. Curr Opin Hematol. 1998;5(5):350\u20134.","journal-title":"Curr Opin Hematol"},{"issue":"07","key":"328_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1055\/s-0037-1613602","volume":"90","author":"A Gerhardt","year":"2003","unstructured":"Gerhardt A, Scharf RE, Zotz RB. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost. 2003;90(07):77\u201385.","journal-title":"Thromb Haemost"},{"issue":"2","key":"328_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/(SICI)1096-8652(199706)55:2<59::AID-AJH2>3.0.CO;2-1","volume":"55","author":"EM Faioni","year":"1997","unstructured":"Faioni EM, et al. Resistance to activated protein C in unselected patients with arterial and venous thrombosis. Am J Hematol. 1997;55(2):59\u201364.","journal-title":"Am J Hematol"},{"issue":"5","key":"328_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s12185-009-0447-6","volume":"90","author":"O Yokus","year":"2009","unstructured":"Yokus O, et al. Risk factors for thrombophilia in young adults presenting with thrombosis. Int J Hematol. 2009;90(5):583\u201390.","journal-title":"Int J Hematol"},{"issue":"3","key":"328_CR34","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1532\/LH96.05029","volume":"11","author":"EJ Favaloro","year":"2005","unstructured":"Favaloro EJ, et al. Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S, and antithrombin deficiency and the potential high risk of a false positive diagnosis. Lab Hematol. 2005;11(3):174\u201384.","journal-title":"Lab Hematol"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00328-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-021-00328-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-021-00328-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T16:49:01Z","timestamp":1634662141000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-021-00328-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["328"],"URL":"https:\/\/doi.org\/10.1186\/s12959-021-00328-0","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]},"assertion":[{"value":"16 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures have been approved by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was signed prior to participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}